Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions reflect a positive reception of the study, with comments highlighting that only patients with lower homocysteine levels benefited from omega-3 supplements, and references to cognitive measures like MMSE and CDR suggest moderate interest. The tone is informative and slightly optimistic, emphasizing the potential importance of homocysteine levels in Alzheimer's treatment without overhyping the results.
Most posts acknowledge the significance of the findings, especially regarding the link between homocysteine levels and omega-3 efficacy, showing a general consensus that the study offers valuable insights.
Discussions demonstrate high interest, with commenters emphasizing the potential implications for Alzheimer's treatment and referencing specific test results like MMSE and CDR which indicates engagement with the research details.
Posts include mentions of the study's methodology and implications, such as the role of B vitamin status and cognitive outcomes, but lack deep critique or alternative viewpoints, reflecting moderate engagement.
While some express optimism about the findings influencing future therapies, the overall tone suggests the impact is seen as noteworthy but not revolutionary, indicating a moderate perceived effect.
Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer’s Disease: The OmegAD Study https://t.co/tHJkFJYpuw Full link to study: https://t.co/NXkObkzoFP
#Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on #Cognition in a Randomized Clinical #Trial in Mild to Moderate #Alzheimer’s Disease Attn: @NathanMDCunha @NaumovskiNenad @DocAmen https://t.co/PdXFQueg9N
RT @HealthyFellow: #Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on #Cognition in a Randomized Clinical #Trial…
RT @HealthyFellow: #Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on #Cognition in a Randomized Clinical #Trial…
In OmegaAD trial, ppl with Alzheimer’s disease took 2.3 g of omega-3 (mostly DHA) for 6 months. Only those with lower homocysteine seemed to see cognitive benefits from taking omega-3s according to a couple tests (MMSE, CDRsob). https://t.co/Q13Y9krhtR https://t.co/QL6msuV5Yy
RT @HealthyFellow: #Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on #Cognition in a Randomized Clinical #Trial…
Most people use omega-3 incorrectly for brain health. Research shows that those with higher DHA levels have a significantly lower risk of dementia. However, randomized trials are inconclusive, suggesting that omega-3…
Does Omega-3 truly benefit the brain or is it a myth? This video examines recent studies on EPA and DHA related to memory, Alzheimer’s, depression, and anxiety disorders. Discover when Omega-3 is effective and why many…
In OmegaAD trial, ppl with Alzheimer’s disease took 2.3 g of omega-3 (mostly DHA) for 6 months. Only those with lower homocysteine seemed to see cognitive benefits from taking omega-3s according to a couple tests (MMSE, CDRsob). https://t.co/Q13Y9krhtR https://t.co/QL6msuV5Yy
RT @Grimhood: Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild…
Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer’s Disease: The OmegAD Study https://t.co/tHJkFJYpuw Full link to study: https://t.co/NXkObkzoFP
RT @HealthyFellow: #Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on #Cognition in a Randomized Clinical #Trial…
RT @HealthyFellow: #Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on #Cognition in a Randomized Clinical #Trial…
RT @HealthyFellow: #Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on #Cognition in a Randomized Clinical #Trial…
#Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on #Cognition in a Randomized Clinical #Trial in Mild to Moderate #Alzheimer’s Disease Attn: @NathanMDCunha @NaumovskiNenad @DocAmen https://t.co/PdXFQueg9N
MM
JF
NC
PP
MP
BY
SK